Imeglimin population pharmacokinetics and dose adjustment predictions for renal impairment in Japanese and Western patients with type 2 diabetes

• Asıl Yazarlar: Yoshiko Tomita (Yazar), Emma Hansson (Yazar), Florent Mazuir (Yazar), Gustaf J Wellhagen (Yazar), Qing Xi Ooi (Yazar), Enrica Mezzalana (Yazar), Atsushi Kitamura (Yazar), Daisuke Nemoto (Yazar), Sébastien Bolze (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: Wiley, 2022-04-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Abstract Imeglimin is an orally administered first‐in‐class drug to treat type 2 diabetes mellitus (T2DM) and is mainly excreted unchanged by the kidneys. The present study aimed to define the pharmacokinetic (PK) characteristics of imeglimin using population PK analysis and to determine the optimal...